HOOKIPA Pharma Inc. (HOOK)
OTCMKTS · Delayed Price · Currency is USD
1.060
+0.010 (0.95%)
Feb 5, 2026, 4:00 PM EST
HOOKIPA Pharma Revenue
HOOKIPA Pharma had revenue of $2.00M in the quarter ending March 31, 2025, a decrease of -94.52%. This brings the company's revenue in the last twelve months to $9.35M, down -82.54% year-over-year. In the year 2024, HOOKIPA Pharma had annual revenue of $43.95M with 118.32% growth.
Revenue (ttm)
9.35M
Revenue Growth
-82.54%
P/S Ratio
1.46
Revenue / Employee
110.01K
Employees
87
Market Cap
13.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43.95M | 23.82M | 118.32% |
| Dec 31, 2023 | 20.13M | 5.88M | 41.27% |
| Dec 31, 2022 | 14.25M | -4.20M | -22.76% |
| Dec 31, 2021 | 18.45M | -1.14M | -5.80% |
| Dec 31, 2020 | 19.58M | 7.64M | 63.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zeo ScientifiX | 5.20M |
| TRON Group | 1.01M |
| Zenith Capital | 500.00K |
| GPL Holdings | 376.54K |
| Provectus Biopharmaceuticals | 350.44K |
HOOKIPA Pharma News
- 2 days ago - HOOKIPA Pharma T0 Sell Oncology Assets HB-200 And HB-700 To NeoTrail Therapeutics - Nasdaq
- 3 days ago - HOOKIPA Pharma to sell oncology assets to NeoTrail Therapeutics - Seeking Alpha
- 3 days ago - HOOKIPA Pharma (HOOK) Divests Key Immuno-Oncology Assets - GuruFocus
- 3 days ago - HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics - GlobeNewsWire
- 3 months ago - Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma - GuruFocus
- 3 months ago - HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - GlobeNewsWire
- 7 months ago - HOOKIPA Pharma to delist from Nasdaq and liquidate following Gilead asset sale - Seeking Alpha
- 7 months ago - HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock - GlobeNewsWire